Drug intelligence / Profile preview

Neupron

Development stage: Preclinical
Lead developer: AxoNeural Therapeutics
Modality: Nanoparticles → Drug Delivery Systems, Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

**Neupron** is a preclinical intravenous nanoparticle-based enzyme therapy developed by AxoNeural Therapeutics for acute traumatic spinal cord injury. It encapsulates the antioxidant enzymes catalase and superoxide dismutase to neutralize injury-associated reactive oxygen species, reduce oxidative stress, and limit the secondary degeneration cascade after spinal cord trauma. In preclinical rat contusion studies, intravenous administration after injury was reported to reduce secondary injury progression and improve locomotor recovery. ([sbir.gov](https://www.sbir.gov/portfolio/1712485))

Other names: Neupron

Beyond the preview

Go deeper on Neupron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neupron.

Explore the full profile